<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31965551</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1048</StartPage><EndPage>1060</EndPage><MedlinePgn>1048-1060</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-019-00811-7</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating motoneuron (Mn) disease without effective cure currently available. Death of MNs in ALS is preceded by failure of neuromuscular junctions and axonal retraction. Neuregulin 1 (NRG1) is a neurotrophic factor highly expressed in MNs and neuromuscular junctions that support axonal and neuromuscular development and maintenance. NRG1 and its ErbB receptors are involved in ALS. Reduced NRG1 expression has been found in ALS patients and in the ALS SOD1<sup>G93A</sup> mouse model; however, the expression of the isoforms of NRG1 and its receptors is still controversial. Due to the reduced levels of NRG1 type III (NRG1-III) in the spinal cord of ALS patients, we used gene therapy based on intrathecal administration of adeno-associated virus to overexpress NRG1-III in SOD1<sup>G93A</sup> mice. The mice were evaluated from 9 to 16&#xa0;weeks of age by electrophysiology and rotarod tests. At 16&#xa0;weeks, samples were harvested for histological and molecular analyses. Our results indicate that overexpression of NRG1-III is able to preserve neuromuscular function of the hindlimbs, improve locomotor performance, increase the number of surviving MNs, and reduce glial reactivity in the treated female SOD1<sup>G93A</sup> mice. Furthermore, the NRG1-III/ErbB4 axis appears to regulate MN excitability by modulating the chloride transporter KCC2 and reduces the expression of the MN vulnerability marker MMP-9. However, NRG1-III did not have a significant effect on male mice, indicating relevant sex differences. These findings indicate that increasing NRG1-III at the spinal cord is a promising approach for promoting MN protection and functional improvement in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xf2;dol-Caballero</LastName><ForeName>Guillem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Lareu</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verd&#xe9;s</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ariza</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Brualla</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Team P3M, Institut de Neurosciences de la Timone, UMR7289, Aix-Marseille Universit&#xe9; and Centre National de la Recherche Scientifique (CNRS), 13005, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brocard</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Team P3M, Institut de Neurosciences de la Timone, UMR7289, Aix-Marseille Universit&#xe9; and Centre National de la Recherche Scientifique (CNRS), 13005, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Assumpci&#xf3;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain. xavier.navarro@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 08193, Bellaterra, Spain. xavier.navarro@uab.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrando-Grabulosa</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6685-3220</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Aut&#xf2;noma de Barcelona, 08193, Bellaterra, Spain. mireia.herrando@uab.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 08193, Bellaterra, Spain. mireia.herrando@uab.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094131">NRG1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">ErbB receptor</Keyword><Keyword MajorTopicYN="N">motoneuron disease</Keyword><Keyword MajorTopicYN="N">motor system</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">neuregulin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31965551</ArticleId><ArticleId IdType="pmc">PMC7609630</ArticleId><ArticleId IdType="doi">10.1007/s13311-019-00811-7</ArticleId><ArticleId IdType="pii">10.1007/s13311-019-00811-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364:362.</Citation><ArticleIdList><ArticleId IdType="pubmed">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoseki A, Shiga A, Tan CF, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol. 2008;63:538&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438952</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D, Vaz AR. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci. 2014;8:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Navarro X. Amyotrophic lateral sclerosis: current perspectives from basic research to the clinic. Progr Neurobiol. 2015;133:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">26253783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripps ME, Huntley GW, Hof PR, et al. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 1995;92:689&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42685</ArticleId><ArticleId IdType="pubmed">7846037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Santos-Nogueira E, et al. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol. 2001;122:1660&#x2013;1670.</Citation><ArticleIdList><ArticleId IdType="pubmed">21354365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Landers JE. Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets. CNS Neurol Disord Drug Targets. 2010;9:779&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20942785</ArticleId></ArticleIdList></Reference><Reference><Citation>Graffmo KS, Forsberg K, Bergh J, et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23026746</ArticleId></ArticleIdList></Reference><Reference><Citation>Federici T, Boulis NM. Gene-based treatment of motor neuron diseases. Muscle Nerve. 2006;33:302&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">16228969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhardt A, Haase R, Schepers A, et al. Episomal vectors for gene therapy. Curr Gene Ther. 2008;8:147&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18537590</ArticleId></ArticleIdList></Reference><Reference><Citation>Syroid DE, Maycox PR, Burrola PG, et al. Cell death in the Schwann cell lineage and its regulation by neuregulin. Proc Natl Acad Sci USA. 1996;93:9229&#x2013;9234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38624</ArticleId><ArticleId IdType="pubmed">8799183</ArticleId></ArticleIdList></Reference><Reference><Citation>Velanac V, Unterbarnscheidt T, Hinrichs W, et al. Bace1 processing of NRG1 type III produces a myelin-inducing signal but is not essential for the stimulation of myelination. Glia. 2012;60:203&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267053</ArticleId><ArticleId IdType="pubmed">22052506</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricker FR, Lago N, Balarajah S, et al. Axonally derived Neuregulin-1 is required for remyelination and regeneration following nerve injury in adulthood. J Neurosci. 2011;31:3225&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059576</ArticleId><ArticleId IdType="pubmed">21368034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Mart&#xed;nez-Muriana A, Leiva T, et al. Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1G93A ALS mice and after partial muscle denervation. Neurobiol Dis. 2016;95:168&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">27461051</ArticleId></ArticleIdList></Reference><Reference><Citation>Falls DL, Rosen KM, Corfas G, et al. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell. 1993;72:801&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">8453670</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinthorsdottir V, Stefansson H, Ghosh S, et al. Multiple novel transcription initiation sites for NRG1. Gene. 2004;342:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">15527969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasiene J, Komine O, Fujimori-Tonou N, et al. Neuregulin 1 confers neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons. Acta Neuropathol Commun. 2016;4:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758105</ArticleId><ArticleId IdType="pubmed">26891847</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F, Chiang P, Wang J, et al. Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2012;71:104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270561</ArticleId><ArticleId IdType="pubmed">22249457</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Fukuda Y, Yoshimura J, et al. ErbB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013;93:900&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824132</ArticleId><ArticleId IdType="pubmed">24119685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Font I, Sogorb-Esteve A, Javier-Torrent M, et al. Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiol Dis. 2019;124:428&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">30594809</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Oliv&#xe1;n S, Mancera P, et al. Effect of genetic background on onset and disease progression in the SOD1G93A model of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2012;13:302&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">10455399</ArticleId></ArticleIdList></Reference><Reference><Citation>Piedra J, Ontiveros M, Miravet S, et al. Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors. Hum Gene Ther Methods. 2015;26:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25640021</ArticleId></ArticleIdList></Reference><Reference><Citation>Homs J, Pag&#xe8;s G, Ariza L, et al. Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy. Mol Ther Methods Clin Dev. 2014;15:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365866</ArticleId><ArticleId IdType="pubmed">26015946</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro X, Udina E. Chapter 6: Methods and protocols in peripheral nerve regeneration experimental research: part III-electrophysiological evaluation. Int Rev Neurobiol. 2009;87:105&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682635</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Cudkowicz M, Brown RHJR. Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:603&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">16892429</ArticleId></ArticleIdList></Reference><Reference><Citation>Miana-Mena FJ, Mu&#xf1;oz MJ, Yag&#xfc;e G, et al. Optimal methods to characterize the G93A mouse model of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16036427</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55695</ArticleId><ArticleId IdType="pubmed">11328886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhinge A, Namboori SC, Zhang X, et al. Genetic correction of SOD1 mutant iPSCs reveals ERK and JNK activated AP1 as a driver of neurodegeneration in Amyotrophic Lateral Sclerosis. Stem Cell Reports. 2017;8:856&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390134</ArticleId><ArticleId IdType="pubmed">28366453</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulenguez P, Liabeuf S, Bos R, et al. Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury. Nat Med. 2010;16:302&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">20190766</ArticleId></ArticleIdList></Reference><Reference><Citation>Brocard C, Plantier V, Boulenguez P, et al. Cleavage of Na(+) channels by calpain increases persistent Na(+) current and promotes spasticity after spinal cord injury. Nat Med. 2016;22:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">26974309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolpowitz D, Mason TB, Dietrich P, et al. Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron. 2000;25:79&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao J, Wolpowitz D, Role LW, et al. Back signaling by the Nrg-1 intracellular domain. J Cell Biol. 2003;161:1133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172983</ArticleId><ArticleId IdType="pubmed">12821646</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Croslan DR, Harris AE, et al. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke. J Cereb Blood Flow Metab. 2006;26:527&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Xu Z, Ford GD, et al. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia. Brain Res. 2007;1184:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2374743</ArticleId><ArticleId IdType="pubmed">17961519</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Hou Y, Zhao Z, et al. Neuregulin-1 accelerates functional motor recovery by improving motoneuron survival after brachial plexus root avulsion in mice. Neuroscience. 2019;404:510&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">30731156</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb JA, Fischbach GD. Neurotrophic factors increase neuregulin expression in embryonic ventral spinal cord neurons. J Neurosci. 1997;17:1416&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793741</ArticleId><ArticleId IdType="pubmed">9006983</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonanno A, Fischbach GD. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol. 2001;11:287&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">11399426</ArticleId></ArticleIdList></Reference><Reference><Citation>Roysommuti S, Carroll SL, Wyss JM. Neuregulin-1beta modulates in vivo entorhinal-hippocampal synaptic transmission in adult rats. Neuroscience. 2003;121:779&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568036</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Zhang M, Trembak-Duff I, et al. Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic plasticity. Cell Rep. 2014;8:1130&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">25131210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WH, Armanini MP, Nuijens A, et al. Sensory and motor neuron-derived factor. A novel heregulin variant highly expressed in sensory and motor neurons. J Biol Chem. 1995;270:14523&#x2013;14532.</Citation><ArticleIdList><ArticleId IdType="pubmed">7782315</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer D, Yamaai T, Garratt A, et al. Isoform-specific expression and function of neuregulin. Development. 1997;124:3575&#x2013;3586.</Citation><ArticleIdList><ArticleId IdType="pubmed">9342050</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb JA, Khurana TS, Robbins JT, et al. Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development. Development. 1999;126:781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">9895325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallart-Palau X, Tarabal O, Casanovas A, et al. Neuregulin-1 is concentrated in the postsynaptic subsurface cistern of C-bouton inputs to &#x3b1;-motoneurons and altered during motoneuron diseases. FASEB J. 2014;28:3618&#x2013;3632.</Citation><ArticleIdList><ArticleId IdType="pubmed">24803543</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero G, Santos D, Navarro X, et al. Neuregulin 1 reduces motoneuron cell death and promotes neurite growth in an in vitro model of motoneuron degeneration. Front Cell Neurosci. 2018;11:431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767462</ArticleId><ArticleId IdType="pubmed">29375317</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwenk BM, Hartmann H, Serdaroglu A, et al. TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO J. 2016;35:2350&#x2013;2370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5090220</ArticleId><ArticleId IdType="pubmed">27621269</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves CJ, de Santana LP, dos Santos AJ, et al. Early motor and electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis and gender differences on clinical outcome. Brain Res. 2011;1394:90&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">21354109</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Allender E, Wang J, et al. Slowing disease progression in the SOD1 mouse model of ALS by blocking neuregulin-induced microglial activation. Neurobiol Dis. 2018;111:118&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">29278738</ArticleId></ArticleIdList></Reference><Reference><Citation>Allender E, Deol H, Schram S, et al. Neuregulin1 modulation of experimental autoimmune encephalomyelitis (EAE) J Neuroimmunol. 2018;318:56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">29534847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix-Fralish ML, Tawfik VL, Nutile-McMenemy N, et al. Neuregulin 1 is a pronociceptive cytokine that is regulated by progesterone in the spinal cord: implications for sex specific pain modulation. Eur J Pain. 2008;12:94&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">17459743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Deniselle MC, L&#xf3;pez-Costa JJ, Saavedra JP, et al. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. Neurobiol Dis. 2002;11:457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tynyakov-Samra E, Auriel E, Levy-Amir Y, et al. Reduced ErbB4 expression in immune cells of patients with relapsing remitting multiple sclerosis. Mult Scler Int. 2011;2011:561262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197252</ArticleId><ArticleId IdType="pubmed">22096639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier MK, Kosciuczyk K, Tapley L, et al. Dysregulation of the neuregulin-1-ErbB network modulates endogenous oligodendrocyte differentiation and preservation after spinal cord injury. Eur J Neurosci. 2013;38:2693&#x2013;2715.</Citation><ArticleIdList><ArticleId IdType="pubmed">23758598</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh A, Dyck SM, Kataria H, et al. Neuregulin-1 positively modulates glial response and improves neurological recovery following traumatic spinal cord injury. Glia. 2017;65:1152&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">28456012</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh A, Santhosh KT, Kataria H, et al. Neuregulin-1 elicits a regulatory immune response following traumatic spinal cord injury. J Neuroinflammation. 2018;15:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822667</ArticleId><ArticleId IdType="pubmed">29467001</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkas-Kramarski R, Eilam R, Spiegler O, et al. Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes. Proc Natl Acad Sci USA. 1994;91:9387&#x2013;9391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44817</ArticleId><ArticleId IdType="pubmed">7937775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury EJ, Moon LD, Popat RJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002;416:636&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">11948352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Jung KM, Huang YZ, et al. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem. 2002;277:6318&#x2013;6323.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni CY, Murphy MP, Golde TE, et al. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294:2179&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11679632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardi SP, Murtie J, Koirala S, et al. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell. 2016;127:185&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018285</ArticleId></ArticleIdList></Reference><Reference><Citation>Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006;66:6412&#x2013;6420.</Citation><ArticleIdList><ArticleId IdType="pubmed">16778220</ArticleId></ArticleIdList></Reference><Reference><Citation>Krivosheya D, Tapia L, Levinson JN, et al. ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms. J Biol Chem. 2008;283:32944&#x2013;32956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395083</ArticleId><ArticleId IdType="pubmed">18819924</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CG. Distinct roles for Erk1 and Erk2 in pathophysiology of CNS. Front Biol. 2012;7:267&#x2013;276.</Citation></Reference><Reference><Citation>Salvany S, Casanovas A, Tarabal O, et al. Localization and dynamic changes of neuregulin-1 at C-type synaptic boutons in association with motor neuron injury and repair. FASEB J. 2019;33:7833&#x2013;7851.</Citation><ArticleIdList><ArticleId IdType="pubmed">30912977</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Roselli F, Singh K, et al. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron. 2013;80:80&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24094105</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs A, Ringer C, Bilkei-Gorzo A, et al. Downregulation of the potassium chloride cotransporter KCC2 in vulnerable motoneurons in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2010;69:1057&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">20838240</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol L, Mancuso R, Al&#xe9; A, et al. Differential effects on KCC2 expression and spasticity of ALS and traumatic injuries to motoneurons. Front Cell Neurosci. 2014;8:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900854</ArticleId><ArticleId IdType="pubmed">24478630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan A, Spiller KJ, Towne C, et al. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron. 2014;81:333&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015650</ArticleId><ArticleId IdType="pubmed">24462097</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X, Zhou H, Huang Y, et al. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis. 2006;23:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857362</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Smith SB, Khoutorsky A, et al. Epiregulin and EGFR interactions are involved in pain processing. J Clin Invest. 2017;127:3353&#x2013;3366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669538</ArticleId><ArticleId IdType="pubmed">28783046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>